Cite
HARVARD Citation
Reches, A. et al. (2020). Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. Journal for immunotherapy of cancer. 8 (1), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Reches, A. et al. (2020). Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. Journal for immunotherapy of cancer. 8 (1), p. . [Online].